Richard Marsden, chief executive of Synairgen plc (LON:SNG) tells Proactive they're to develop their inhaled interferon beta drug SNG001 as a potential treatment for chronic obstructive pulmonary disease (COPD) after a review of data indicated it can boost the lungs’ antiviral capabilities.
A short trial is being planned this winter to test the COPD potential.
Marsden also discusses their upcoming LOXL2 trial.
PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.
Results from the Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.